Bora's Q1 EPS Hits 8-Year Low at NT$0.21, Shrinking 98% Year-on-Year
Bora Pharmaceuticals announced its first-quarter net profit attributable to the parent company was NT$25.83 million, a 98.1% decrease year-on-year, with an EPS of NT$0.21, an 8-year low. The company cited headwinds in the US generics market and plant maintenance but notes that orders are recovering.
📋 Article Processing Timeline
- 📰 Published: May 13, 2026 at 19:09
- 🔍 Collected: May 13, 2026 at 19:32 (22 min after Published)
- 🤖 AI Analyzed: May 13, 2026 at 19:56 (24 min after Collected)
Taipei, May 13 (CNA) - Bora Pharmaceuticals today announced its first-quarter financial report, with revenue of NT$4.001 billion, a decrease of 10.6% year-on-year and 17.6% quarter-on-quarter. Net profit attributable to the parent company was NT$25.83 million, a 92.1% decrease quarter-on-quarter and a significant 98.1% shrinkage compared to the same period last year. The quarterly earnings per share (EPS) of NT$0.21 set an 8-year low.
Bora explained that in the first quarter of this year, the company's dual-engine business faced phase-specific headwinds, including price and demand fluctuations in the U.S. generic drug market in January and February, which caused Upsher-Smith's revenue to decline compared to the average of the last four quarters. Simultaneously, the sterile injectable plant in Maryland underwent its scheduled semi-annual maintenance. Due to the higher fixed costs of the sterile injectable plant, this also put pressure on quarterly profits.
However, Bora stated that since March, the group's revenue and profit have gradually stabilized. The most encouraging sign is the significant order momentum at the Maple Grove facility in the U.S. Bora's strategic investments are expected to pay off successively over the next 12 months.
Bora stated that the order momentum for its CDMO (Contract Development and Manufacturing Organization) business remains strong. As of the end of March, the order backlog for the next 12 months increased to US$315 million, a significant climb from US$264 million at the end of 2025.
Bora pointed out that the company's board of directors recently approved the acquisition of the CDMO business of the U.S. listed company MacroGenics for a total consideration of US$122.5 million. Upon completion of the transaction, the order backlog will further increase to approximately US$375 million, which will immediately inject new momentum into Bora's CDMO business.
In addition, the board of directors of Bora Group's subsidiary, Sunway Biotech, also recently approved the 100% equity acquisition of the American sports nutrition brand Weider Global Nutrition (WGN). The brand is headquartered in Phoenix, USA, has a strategic supplier relationship with the American hypermarket Costco, operates in more than 60 countries, and has stable sales points on Amazon, Walmart, and others. (Editor: Pan Yi-ching) 1150513
Bora explained that in the first quarter of this year, the company's dual-engine business faced phase-specific headwinds, including price and demand fluctuations in the U.S. generic drug market in January and February, which caused Upsher-Smith's revenue to decline compared to the average of the last four quarters. Simultaneously, the sterile injectable plant in Maryland underwent its scheduled semi-annual maintenance. Due to the higher fixed costs of the sterile injectable plant, this also put pressure on quarterly profits.
However, Bora stated that since March, the group's revenue and profit have gradually stabilized. The most encouraging sign is the significant order momentum at the Maple Grove facility in the U.S. Bora's strategic investments are expected to pay off successively over the next 12 months.
Bora stated that the order momentum for its CDMO (Contract Development and Manufacturing Organization) business remains strong. As of the end of March, the order backlog for the next 12 months increased to US$315 million, a significant climb from US$264 million at the end of 2025.
Bora pointed out that the company's board of directors recently approved the acquisition of the CDMO business of the U.S. listed company MacroGenics for a total consideration of US$122.5 million. Upon completion of the transaction, the order backlog will further increase to approximately US$375 million, which will immediately inject new momentum into Bora's CDMO business.
In addition, the board of directors of Bora Group's subsidiary, Sunway Biotech, also recently approved the 100% equity acquisition of the American sports nutrition brand Weider Global Nutrition (WGN). The brand is headquartered in Phoenix, USA, has a strategic supplier relationship with the American hypermarket Costco, operates in more than 60 countries, and has stable sales points on Amazon, Walmart, and others. (Editor: Pan Yi-ching) 1150513